Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Small Cell Lung Carcinoma 42 Ovarian Neoplasms 33 Fallopian Tube Neoplasms 15 Neoplasms 12 Carcinoma, Ovarian Epithelial 10 Uterine Cervical Neoplasms 7 Recurrence 6 Neuroblastoma 5 Lung Neoplasms 5 Neoplasm Metastasis 4 Carcinoma, Non-Small-Cell Lung 4 Sarcoma, Ewing 3 Endometrial Neoplasms 3 Uterine Cervical Dysplasia 2 Sarcoma, Clear Cell 2 Sarcoma 2 Rhabdomyosarcoma 2 Myoepithelioma 2 Medulloblastoma 2 Liposarcoma, Myxoid 2 Histiocytoma, Angiomatoid Fibrous 2 Hereditary Sensory and Autonomic Neuropathies 2 Diffuse Intrinsic Pontine Glioma 2 Desmoplastic Small Round Cell Tumor 2 Chondrosarcoma, Extraskeletal Myxoid 2 Carcinoma 2 Solid Tumours 1 Solid Tumors 1 Solid Tumor 1 SCLC 1

Interventions

amuvatinib 1 Topotecan 1 Paclitaxel 1 Etoposide 1 Erlotinib Hydrochloride 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Malignant Disease × Topotecan × Clear all

NCT00881166 2024-08-02

SGI-0470-02

Astex Pharmaceuticals, Inc.

Phase 1 Completed

Malignant Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡